Alphabet, Sanofi and Syncona were among the investors helping the drug developer advance toward clinical trials.

OMass Therapeutics, a UK-based small molecule drug developer, is taking novel treatments for inflammatory bowel disease and adrenal conditions to clinical trials with the help of a $100m series B round co-led by internet and technology group Alphabet and pharmaceutical firm Sanofi. Founded in 2016 and spun out of University of Oxford, OMass has developed…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.